Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer
Excerpt from the Press Release:
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ — Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Randi Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs brings to the Werewolf team more than 20 years’ experience as a hematologist and oncologist driving clinical and translational oncology drug development both in academia and biopharma across a range of cancer treatments, including targeted therapies, multi-modality biologics, immunotherapies, and CAR T therapies. She joins the Company from the Novartis Institutes for BioMedical Research (NIBR) and will inform strategy and direction for Werewolf’s clinical development programs in the newly formed role.
Click the button below to continue reading the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?